Goldman Sachs raises weight-loss drug market forecast: Oral GLP-1 to enter the mass market, with a projected size of $114 billion by 2030.

With the rapid opening of the market for oral GLP-1 class weight loss drugs, Goldman Sachs has further increased its growth expectations for the global obesity drug industry. The latest research report released by Goldman Sachs shows that by 2030, the global weight loss drug market is expected to reach $114 billion, an increase of about 13% from the previous estimate of $101 billion made in December last year, as a series of favorable factors are driving this industry from a "niche high-priced market" to a "mass consumer market."